Overview

Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The randomized, controlled trial is to investigate and evaluate the effects of short-term continuous subcutaneous insulin infusion (CSII) sequential exenatide therapy on β-cell function, long-term glycemic control and glycemic remission rate in newly diagnosed type 2 diabetic patients.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Treatments:
Exenatide
Insulin
Insulin Lispro
Insulin, Globin Zinc